L E Diamond

Summary

Affiliation: Palatin Technologies
Country: USA

Publications

  1. ncbi request reprint Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction
    L E Diamond
    Palatin Technologies, Inc, Cranbury, New Jersey 08540, USA
    Int J Impot Res 16:51-9. 2004
  2. ncbi request reprint Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response
    L E Diamond
    Palatin Technologies, Inc, Cranbury, New Jersey 08512, USA
    Urology 65:755-9. 2005
  3. ncbi request reprint PT-141: a melanocortin agonist for the treatment of sexual dysfunction
    P B Molinoff
    Palatin Technologies, Inc, Cranbury, New Jersey 08512, USA
    Ann N Y Acad Sci 994:96-102. 2003
  4. ncbi request reprint Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra
    R C Rosen
    Department of Psychiatry, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08554 5653, USA
    Int J Impot Res 16:135-42. 2004

Collaborators

Detail Information

Publications4

  1. ncbi request reprint Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction
    L E Diamond
    Palatin Technologies, Inc, Cranbury, New Jersey 08540, USA
    Int J Impot Res 16:51-9. 2004
    ..Based upon its erectogenic potential and tolerability profile, PT-141 is a promising candidate for further evaluation as a treatment for male ED...
  2. ncbi request reprint Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response
    L E Diamond
    Palatin Technologies, Inc, Cranbury, New Jersey 08512, USA
    Urology 65:755-9. 2005
    ..To evaluate the safety and pharmacodynamic effect of co-administration of subtherapeutic doses of PT-141, a cyclic heptapeptide melanocortin analogue, and sildenafil to patients with erectile dysfunction...
  3. ncbi request reprint PT-141: a melanocortin agonist for the treatment of sexual dysfunction
    P B Molinoff
    Palatin Technologies, Inc, Cranbury, New Jersey 08512, USA
    Ann N Y Acad Sci 994:96-102. 2003
    ..Administration of PT-141 to normal men and to patients with erectile dysfunction resulted in a rapid dose-dependent increase in erectile activity. The results suggest that PT-141 holds promise as a new treatment for sexual dysfunction...
  4. ncbi request reprint Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra
    R C Rosen
    Department of Psychiatry, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08554 5653, USA
    Int J Impot Res 16:135-42. 2004
    ....